Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afimkibart (PF-06480605) in moderate to severe Crohn's Disease
NCT05471492Phase 2Withdrawn
- Sponsor
- Telavant
- Start
- Jul 2023
- Primary completion
- Aug 2026
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
01
Overview
A Phase 2 trial of afimkibart in Crohn's disease, sponsored by Telavant. Planned start Jul 2023; status: withdrawn.
02
Drugs
afimkibart
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT05471492.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05471492.